5-MeO-DMT – Kodiac biolabs

Plain-language summaryIntrigue 76 / 100

5-MeO-DMT is a tryptamine psychedelic chemically related to DMT but with strikingly different pharmacology: it prefers the 5-HT1A receptor over 5-HT2A, the opposite of N,N-DMT, which produces a qualitatively distinct experience generally described as an undifferentiated state rather than the visionary content of classical psychedelics. It is concentrated in the parotoid gland secretions of the Sonoran Desert toad (Bufo alvarius), the source of toad medicine ceremonies, and is found in several plants used in South American snuffs. Clinical interest in single-dose treatment for depression and substance use disorders is growing, with several small studies underway. The intensity and brevity of the experience pose unusual clinical and safety challenges. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

57/100

Unique 5-HT1A-preferring psychedelic probe with active phase 2 TRD programs and strong mechanistic differentiation from classical psychedelics

Look, 5-MeO-DMT earns its attention not by being flashy but by being genuinely distinct from everything else in its class. The receptor profile is the whole story: while N,N-DMT and psilocin hit 5-HT2A with high affinity and drive classic visual geometry, 5-MeO-DMT’s 5-HT1A Ki runs around 1 nM versus a 5-HT2A Ki that’s roughly 100-fold weaker. That preference inversion is not a minor pharmacological footnote. It makes 5-MeO-DMT the cleanest reference compound available for disentangling 5-HT1A from 5-HT2A contributions in psychedelic pharmacology, and right now, that question is genuinely live in the field.

The mechanism case is interesting. 5-HT1A agonism at serotonergic autoreceptors and postsynaptic raphe targets produces anxiolytic and potentially antidepressant effects through routes that are materially different from 5-HT2A-mediated neuroplastic signaling. Researchers at GH Research and Beckley Psytech are running phase 2 trials in treatment-resistant depression, and part of what makes those programs scientifically interesting is exactly this receptor distinction. The compound also has a pharmacokinetic profile thats unusual for a psychedelic: smoked or vaporized, onset is nearly immediate and plasma half-life runs 12 to 19 minutes. That short window has real practical implications for clinical protocol design that longer-acting compounds don’t easily accommodate.

What we like here is the probe value. If you’re asking how much of the therapeutic signal in psychedelic-assisted work comes from 5-HT1A versus 5-HT2A, 5-MeO-DMT is one of very few tools that gives you a meaningful handle on that question. The qualitatively distinct subjective profile, less visual and more unitary or dissociative, is itself informative data from a mechanistic standpoint. Thats not nothing in a field where receptor-attribution debates are still very much unresolved.

What limits the score is straightforward. The controlled human evidence base is early. Phase 2 is ongoing, not reported, and small-N observational data from naturalistic or ceremonial contexts doesn’t substitute for replicated controlled data. The preclinical literature is thinner and more heterogeneous in quality than psilocybin’s comparable corpus. And Schedule I status in the US creates real research logistics friction that most bench labs can’t absorb without dedicated infrastructure, which matters for practical feasibility regardless of scientific interest.

We think serious psychedelic pharmacology researchers should know this compound well. It’s not an across-the-board priority, but as a mechanistic probe for 5-HT1A-preferring psychedelic biology it’s close to irreplaceable. The phase 2 readouts from GH Research and Beckley Psytech will matter; if those data come back with a clear signal, this score moves.

Novelty: 52
Mechanism promise: 65
In-category differentiation: 68
Evidence quality: 42
Translational signal: 45
Research bench value: 68

Rationale 5-MeO-DMT’s 5-HT1A preference (Ki ~1 nM vs 5-HT2A Ki ~100 nM) makes it pharmacologically unique among research psychedelics, giving it genuine probe value for disentangling receptor contributions to psychedelic effects. Score is constrained by early-stage human evidence and Schedule I logistics friction; the GH Research and Beckley Psytech phase 2 readouts will be the decisive data event for this compound.

Indolealkylamine tryptamine psychedelic with preferential 5-HT1A receptor agonism and broad serotonergic activity

A naturally occurring 5-methoxy-substituted tryptamine distinguished from classical psychedelics by preferential high-affinity 5-HT1A receptor agonism, ultra-short duration of action, and emerging Phase 2 clinical evidence in treatment-resistant depression.

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT; CAS 1019-45-0; molecular formula C13H18N2O; molecular weight 218.30 g/mol) is a naturally occurring indolealkylamine tryptamine psychedelic first synthesized by Hoshino and Shimodaira in 1936, subsequently identified as a constituent of Anadenanthera peregrina seeds, Virola species bark resins, and the parotoid gland secretions of the Sonoran Desert toad Incilius alvarius (formerly Bufo alvarius). The compound is pharmacologically distinguished from other tryptamine psychedelics (N,N-dimethyltryptamine, psilocin, bufotenine) by a receptor binding profile that strongly favors the serotonin 5-HT1A receptor (Ki approximately 1.9 to 3 nM) over the 5-HT2A receptor (Ki approximately 900 nM), producing a 300- to 1000-fold selectivity ratio that inverts the binding preference of the classical 5-HT2A-preferring psychedelics. Functional pharmacology demonstrates full agonist activity at 5-HT1A receptors and partial to full agonism at 5-HT2A receptors, with additional binding at the serotonin transporter (SERT), sigma-1 receptors, and trace amine-associated receptor 1 (TAAR1).

The subjective psychedelic experience produced by inhaled 5-MeO-DMT is characterized by a rapid onset (30 to 60 seconds), intense peak (5 to 15 minutes), and brief total duration (15 to 20 minutes), rendering the compound the shortest-acting of the classical tryptamine psychedelics. The ultra-short duration and the predominance of 5-HT1A-mediated pharmacology produce qualitative differences from 5-HT2A-preferring psychedelics: less visual perceptual distortion, more ego-dissolution and dissociative phenomenology, and high scores on mystical experience questionnaires comparable to high-dose psilocybin.

Metabolism proceeds through two principal pathways. Monoamine oxidase A (MAO-A) catalyzes oxidative deamination to 5-methoxyindoleacetic acid, the primary inactivation route that accounts for the rapid systemic clearance and the oral inactivity of the compound in the absence of MAO inhibition. Cytochrome P450 2D6 (CYP2D6) catalyzes O-demethylation to bufotenine (5-hydroxy-N,N-dimethyltryptamine), a pharmacologically active metabolite with preferential 5-HT2A receptor affinity. CYP2D6 polymorphism substantially modulates the bufotenine metabolic fraction; poor metabolizers produce less bufotenine but experience prolonged parent compound exposure, while ultrarapid metabolizers generate more bufotenine with potential for additive serotonergic burden. The dual-enzyme metabolic architecture creates clinically significant drug-drug interactions, most critically with MAO inhibitors (harmine, harmaline, moclobemide, phenelzine, tranylcypromine), which increase 5-MeO-DMT systemic exposure 3.6- to 4.4-fold and bufotenine exposure 6.1- to 9.9-fold, with documented risk of serotonin toxicity and fatalities.

Clinical development is led by GH Research (Dublin), whose inhalable mebufotenin formulation GH001 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial in 81 patients with treatment-resistant depression (TRD), demonstrating a placebo-adjusted Montgomery-Asberg Depression Rating Scale (MADRS) reduction of 15.5 points at day 8 and remission rates of 77.8 percent at 6 months in the open-label extension (announced February 2025). A Phase 1/2 open-label trial (Reckweg et al. 2023) in 12 TRD patients reported 87.5 percent remission at day 7 and no serious adverse events. Preclinical pharmacology demonstrates neuroplasticity effects including increased dendritic spine density in mouse medial frontal cortex, increased neurogenesis in the dentate gyrus, and anxiolytic effects in stressed animal models. The compound is classified as Schedule I in the United States, is not approved by any regulatory authority for medical use, and all research applications are subject to controlled substance research licensure. This monograph reviews the chemistry, natural occurrence, dual-enzyme metabolism, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, safety signal, sourcing, reconstitution, stack interactions, and a comparative assessment of five tryptamine psychedelic candidates against 5-MeO-DMT on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-341Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.